1. Home
  2. LTC vs AGIO Comparison

LTC vs AGIO Comparison

Compare LTC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LTC Properties Inc.

LTC

LTC Properties Inc.

HOLD

Current Price

$36.19

Market Cap

2.0B

Sector

Real Estate

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$33.13

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTC
AGIO
Founded
1992
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
1994
2013

Fundamental Metrics

Financial Performance
Metric
LTC
AGIO
Price
$36.19
$33.13
Analyst Decision
Hold
Buy
Analyst Count
5
8
Target Price
$40.00
$38.88
AVG Volume (30 Days)
470.8K
896.9K
Earning Date
05-06-2026
04-29-2026
Dividend Yield
5.96%
N/A
EPS Growth
23.53
N/A
EPS
0.48
N/A
Revenue
$262,854,000.00
$43,011,000.00
Revenue This Year
N/A
$76.75
Revenue Next Year
N/A
$170.73
P/E Ratio
$76.83
N/A
Revenue Growth
25.26
N/A
52 Week Low
$33.64
$22.24
52 Week High
$40.80
$46.00

Technical Indicators

Market Signals
Indicator
LTC
AGIO
Relative Strength Index (RSI) 41.04 67.71
Support Level $35.52 $32.47
Resistance Level $37.00 $36.07
Average True Range (ATR) 0.91 1.58
MACD 0.04 0.54
Stochastic Oscillator 45.30 90.86

Price Performance

Historical Comparison
LTC
AGIO

About LTC LTC Properties Inc.

LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: